| Literature DB >> 2464699 |
E J Buxton1, C A Meanwell, C Hilton, J J Mould, D Spooner, A Chetiyawardana, T Latief, M Paterson, C W Redman, D M Luesley.
Abstract
We report a phase II study of bleomycin, ifosfamide, and cisplatin (BIP) in cervical cancer. Our aims were to assess response rate, toxicity, and survival in women treated with this combination. Among 49 patients, 34 objective responses (69%) were seen, with 10 complete responses (20%). Toxic effects were assessed in 186 treatment cycles. All patients had alopecia and nausea and vomiting. Other effects included myelosuppression, infection, reduction in renal function, and disturbance of consciousness. These data indicate that BIP is highly active against advanced and recurrent cervical cancer.Entities:
Mesh：
Substances：
Year: 1989 PMID： 2464699 DOI： 10.1093/jnci/81.5.359
Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506